According to information from a new study, women suffering from morbid obesity and atrial fibrillation are at an increased risk of experiencing complications after having a catheter ablation. The study was conducted by Dr. M. Benjamin Shoemaker M.D. and colleagues, and was published online in the American Journal of Cardiology.

The study was conducted with researchers analyzing retrospective data collected from 445 obese participants with AF who had undergone catheter ablations. During the study, researchers noted that the participants had a total of 512 ablation procedures performed, and of them, 260 in patients were 61 or older, 210 of them were aged 57-60 and 42 patients were morbidly obese. Researchers learned after analyzing their post-operative complications that the rates were higher in the obese patients at 14.3 percent when compared to the patients who weren’t obese (6.2 percent). The researchers also found that the morbidly obese women had a significantly higher complication rate at 25 percent than the men who were morbidly obese (7.7 percent). What this basically means is that obese women are more likely to suffer from complications after catheter ablation surgery than obese men.

Catheter ablation is just one method used to treat patients with atrial fibrillation. Another method for treating AF is with prescription drugs like Multaq, which aims to prevent strokes and AF recurrences. So far, prescription drugs are popular deterrents from recurrences of AF. However, Multaq has been found to be too dangerous for use because of the side effects linked to it. Some of the serious side effects linked to Multaq include a worsening of the heart condition, liver failure, lung disease and pulmonary toxicity.

If you or a loved one has suffered from liver failure, a worsening of the heart condition, lung disease or pulmonary toxicity after taking Multaq, contact attorney Greg Jones for a free consultation today. I am experienced at fighting Multaq lawsuits and may be able to help you recover money for your injuries.